Haleon floated on the London Stock Exchange in July with a value of more than £30 billion (Haleon/PA)
Increasing sales of healthcare brands including Panadol, Advil and Centrum pushed operating profits at Haleon up 22% as it reported its first set of results since becoming a standalone company.
Revenues also jumped 13.4% to £5.19 billion in the six months to the end of June, and Haleon said it is “well positioned to navigate the current macro-economic challenges including rising inflation and the potential impact this may have on consumer behaviour in the future”.
